Nintedanib in systemic sclerosis treatment: a case report
Abstract Background Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced expiratory volume. Case presentation A 48-year-old Asian female patient with systemic scleroderma 6 years ago developed breathlessness, nausea, he...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Journal of Medical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13256-024-04433-2 |